Madrigal PHARMACEUTICALS, Inc. (MDGL) intrinsic value & 10-year financials
Madrigal PHARMACEUTICALS, Inc. (MDGL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 432.1% a year to $958.4M, with an average return on invested capital of -148.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $449.74
- Market cap
- $10.1B
- Revenue (FY2025)
- $958.4M
- Revenue growth (10-yr CAGR)
- 432.1%
- ROIC (10-yr avg)
- -148.1%
- Free cash flow (FY2025)
- -$190.0M
MDGL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $958.4M | -$288.3M | -$12.85 | -$190.0M | -31.3% | -39.4% |
| FY2024 | $180.1M | -$465.9M | -$21.90 | -$457.0M | -276.4% | -83.3% |
| FY2023 | $0 | -$373.6M | -$19.99 | -$325.7M | — | -225.7% |
| FY2022 | $0 | -$295.4M | -$17.23 | -$225.1M | — | -779.2% |
| FY2021 | $0 | -$241.8M | -$14.63 | -$184.1M | — | -139.9% |
| FY2020 | $0 | -$202.2M | -$13.09 | -$157.9M | — | -74.3% |
| FY2019 | $0 | -$83.9M | — | -$41.8M | — | -25.7% |
| FY2018 | $0 | -$32.8M | — | -$25.5M | — | -12.3% |
| FY2017 | $0 | -$31.2M | — | -$22.4M | — | -28.5% |
| FY2016 | — | -$26.4M | — | -$17.6M | — | -72.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MADRIGAL PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MADRIGAL PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -48.6% ROIC.
MADRIGAL PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MADRIGAL PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-426.82 per share.